HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb
References (14)
- et al.
Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis-B virus infected patients treated for non-Hodgkin's lymphoma
Blood
(2002) - et al.
Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface carriers
Blood
(2002) - et al.
Fatal hepatitis B virus reactivationby an escape mutant following rituximab therapy
Blood
(2003) Occult hepatitis B infection
Transfus Clin Biol
(2004)- et al.
Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA
Lancet
(1995) - et al.
Frequency of hepatitis B virus reactivation in cancer patientsundergoing cytotoxic chemotherapy: a prospective study of 626patients with identification of risk factors
J Med Virol
(2000) - et al.
Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies
Eur J Haematol
(2001)
There are more references available in the full text version of this article.
Cited by (113)
Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients
2012, Journal of HepatologyManagement of chemotherapy-induced hepatitis B virus reactivation
2012, Journal of the Chinese Medical AssociationViral outcome in patients with occult HBV infection or HCV-Ab positivity treated for lymphoma
2017, Annals of HepatologySafety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
2020, Journal for ImmunoTherapy of Cancer
Copyright © 2005 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.